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ABSTRACT
Acute graft-versus-host disease (aGVHD) is partly mediated through activated T cells, and these cells are
known to express the high-affinity receptor for interleukin 2 (IL-2R). Denileukin diftitox is composed of
human IL-2 and diphtheria toxin that is cytotoxic to activated lymphocytes expressing the high-affinity IL-2R.
We describe the results of a phase II study of denileukin diftitox in 22 patients with steroid-resistant aGVHD.
Twenty patients were treated at dose level 1 (4.5 g/kg daily on days 1-5 and then weekly on study days 8, 15,
22, and 29), and 2 patients were treated at dose level 2 (9.0 g/kg delivered on the same schedule). Dose level
2 was associated with grade 3/4 renal and hepatic toxicity and vascular leak syndrome, and no further patients
were treated at this level. Dose level 1 was generally well tolerated. The response of aGVHD was assessed at
study days 36 and 100. Nine patients (41%) responded, all with a complete response at study day 36, and 6
patients (27%) responded at study day 100 (4 complete responses and 2 partial responses). Denileukin diftitox
has promising activity in steroid-resistant aGVHD, and further study is warranted.
© 2005 American Society for Blood and Marrow Transplantation
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Acute graft-versus-host disease (aGVHD) occurs
n approximately 40% to 60% of patients who receive
tem cells from an HLA-matched sibling and in 60%
o 80% of those who receive stem cells from HLA-
atched unrelated donors [1-3]. Data from several
arge series report that approximately 50% of patients
btain an initial response of their aGVHD with the
ddition of 1 to 2 mg/kg corticosteroids as part of
heir primary therapy for aGVHD [1,2,4]. However,
nly 30% of patients are eventually able to be tapered
ff steroids and maintain a durable complete response
CR) to primary therapy [4]. Complications from
hronic GVHD and long-term steroid use compro-
ise quality of life and increase morbidity and mor-
ality in patients with steroid resistant aGVHD.
The pathophysiology of aGVHD is partly medi-ted by activated T cells that are derived from the h
88onor and alloreactive against the recipient [5]. The
igh-afﬁnity interleukin 2 receptor (IL-2R) is ex-
ressed on activated T cells [6]. This receptor is a
rotein multimer composed of an alpha chain (55 kd;
D25), beta chain (p75; CD122), and gamma chain
p64; CD132). All 3 proteins together constitute the
igh-afﬁnity IL-2R [7,8]. Signal transduction occurs
hrough this complex via the binding of IL-2 to the
igh-afﬁnity receptor. This binding triggers a series of
vents that result in the enhancement of lymphocyte
roliferation and differentiation [9,10]. The restric-
ion of this high-afﬁnity complex to activated lympho-
ytes makes it an attractive target for strategies de-
igned to selectively eliminate alloreactive T cells.
Denileukin diftitox is a recombinant fusion pro-
ein composed of amino acid sequences for diphtheria
oxin fragments A and B followed by the sequences for
uman IL-2 [11]. Denileukin diftitox preferentially
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Binds to the high-afﬁnity IL-2R and intoxicates acti-
ated T lymphocytes by receptor-mediated endocyto-
is. Once internalized into an acidic vesicle, the enzy-
atically active fragment A portion is released into the
ytosol. Protein synthesis is inhibited via fragment
–catalyzed adenine diphosphate ribosylation of elon-
ation factor 2 and ultimately results in cell death
12,13]. We theorized that denileukin diftitox would
e an active agent in the treatment and prevention of
GVHD because it selectively targets and kills cells
hat express the high-afﬁnity IL-2R. We report the
esults of a phase I/II study investigating the safety and
fﬁcacy of denileukin diftitox in patients with steroid-
esistant aGVHD.
ATERIALS AND METHODS
atients
Institutional review boards at each participating
enter approved the study design. Written informed
onsent was obtained from patients before treatment.
iagnosis was made clinically with biopsy conﬁrma-
ion in at least 1 involved organ system. Criteria for
teroid-resistant aGVHD were deﬁned to capture pa-
ients who experienced treatment failure with primary
herapy for aGVHD (Table 1). The study was de-
igned to treat patients at ﬁrst diagnosis of steroid-
esistant disease, and, therefore, patients were ex-
luded if they received systemic immunosuppressive
reatment for aGVHD other than systemic corticoste-
oids and continuation of baseline prophylactic med-
cations for aGVHD. Patients were also excluded if
hey had a serum creatinine 2 times the upper limit
f normal, respiratory failure, severe veno-occlusive
able 1. Criteria for Steroid-Resistant Acute GVHD
riteria I
Methylprednisolone 2 mg/kg for 3 d plus one of the following:
Skin rash >50%
Bilirubin >8 mg/dL
Diarrhea 1500 mL/d (21 mL/kg/d for children) with or
without severe pain or ileus
Progressive aGVHD
riteria II
Methylprednisolone 2 mg/kg or equivalent for 7 d plus one of
the following:
Rash >25%
Bilirubin >3.5 mg/dL; diarrhea >500 mL/d (children 7 mL/
kg/d)
N/V, pain, or UGI histology
No response or progression
riteria III
Flare of aGVHD symptoms with taper of methylprednisolone
or equivalent to less than 2 mg/kg/d
iopsy was required of at least 1 organ system involved to document
pathologic conﬁrmation of aGVHD.
/V indicates nausea/vomiting; UGI, upper gastrointestinal tract.isease, or uncontrolled infection. c
B&MTThe study was designed to evaluate 2 dose levels of
enileukin diftitox (Ontak; Ligand Pharmaceuticals
nc., San Diego, CA). Dose level 1 was 4.5 g/kg days
to 5 and then weekly on study days 8, 15, 22, and 29.
ose level 2 was 9.0 g/kg days 1 to 5 and then weekly
n study days 8, 15, 22, and 29. The dose was based on
deal body weight and was administered intravenously
ver 15 to 60 minutes. The treating physician was
llowed to taper steroids after denileukin diftitox
reatment had started by following a suggested sched-
le of a 25% weekly decrease in steroid dose when the
otal steroid dose was 1 mg/kg/d and then 10%
eekly when the total steroid dose was 1 mg/kg/d.
efinition of Outcomes
Response of aGVHD at study days 36 and 100 was
he primary end point of the study. Patients who had
GVHD that did not respond or progressed or that
ared after an initial response or those who died be-
ore study day 36 or 100 were considered nonre-
ponders. Progression was deﬁned as at least a 1-stage
ncrease in aGVHD in at least 1 organ system. Pa-
ients who did not respond or progressed were taken
ff the study and allowed to receive other therapy for
GVHD, but they were deemed nonresponders and
ere followed up for outcome. CR in an organ was
eﬁned as complete resolution of GVHD in that or-
an system, and a partial response (PR) was deﬁned as
1-stage decrease in the involved organ system. For
verall assessment, CR was deﬁned as complete reso-
ution of GVHD in all involved organ systems, and
R was deﬁned as at least a 1-stage decrease of
GVHD in 1 organ system without worsening or new
GVHD symptoms in another organ system.
The treating physician graded GVHD by using
he International Bone Marrow Transplant Registry
everity index [14], and toxicity was graded by Com-
on Terminology Criteria for Adverse Events [15]. Pa-
ients were monitored for toxicity during the admin-
stration of study drug, and GVHD and toxicity
rading were performed weekly for the ﬁrst 5 weeks
nd at study day 100.
tatistical Analysis
The study was designed as a 2-stage phase II
esign [16]. If no responses were seen in the ﬁrst 14
atients treated at dose level 1, patients were then to
e assigned to dose level 2. Initial responses were seen
t dose level 1, and the protocol was amended after 20
atients were treated to allow accrual to begin at dose
evel 2.
ESULTS
atient Characteristics
Twenty-two patients were enrolled, and their
haracteristics are described in Table 2. All patients
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1ere evaluated for response. Twenty patients were
reated at dose level 1, and 2 patients were treated at
ose level 2.
VHD Response
At study day 36, 9 patients (41%) had responded,
ll with a CR. At study day 100, 6 patients (27%) had
esponded: 4 patients (18%) with a CR and 2 patients
9%) with a PR. All responders at study day 100 were
lso responders at study day 36. Of the 13 patients
oded as nonresponders at study day 36, 3 patients
ied of infection with responding GVHD, 3 patients
ad no response or progression of GVHD, and 7
atients had an initial response but then progression
f their GVHD symptoms. All 4 patients with a CR at
tudy day 100 also had a CR at study day 36. Response
y grade of GVHD at study entry and stage of organ
nvolvement are listed in Table 3.
oxicity
All patients were assessed for toxicity. The 2 pa-
able 2. Patient Characteristics
Variable Data
22
edian age, y (range) 44 (9–59)
ex (male/female) 12/10
iagnosis
Non-Hodgkin lymphoma/Hodgkin disease 8
Acute leukemia/myelodysplastic syndrome 6
Chronic myelogenous leukemia 5
Multiple myeloma 2
Aplastic anemia 1
onor
Matched related donor 12
Matched unrelated donor 8
One antigen–mismatched unrelated donor 2
tem cell source
Peripheral blood 14
Bone marrow 7
Umbilical cord blood 1
reparative regimen
Bu/Cy 8
Cy/TBI 6
Bu/Flu (reduced intensity) 5
Other 3
VHD prophylaxis
Tacrolimus/methotrexate 17
Cyclosporine/methotrexate 4
Cyclosporine/methylprednisolone 1
riteria for diagnosis of steroid-resistant
aGVHD
Criteria I 5
Criteria II 3
Criteria III 14
VHD grade at study entry
Grade B 7
Grade C 7
Grade D 8
u indicates busulfan; Cy, cyclophosphamide; TBI, total body ir-
radiation; Flu, ﬂudarabine.ients treated at dose level 2 required early cessation of
90tudy drug. One patient stopped treatment after the
rst 4 daily doses secondary to development of vascu-
ar leak syndrome, lower extremity pain, and asthenia.
he other patient developed vancomycin-resistant en-
erococcus sepsis after the ﬁrst weekly dose, followed
y multiorgan system failure and death. Both patients
lso developed grade 3 to 4 hyperbilirubinemia and
ncreases of hepatic transaminases and creatinine.
At dose level 1, no infusion-related reactions were
ocumented. Two patients did develop mild vascular
eaks with isolated lower extremity edema and hy-
oalbuminemia. Median albumin levels for all patients
efore and after denileukin diftitox treatment were
ot signiﬁcantly different (data not shown). No grade
or 4 hyperbilirubinemia or increased hepatic
ransaminases were observed at this dose level. Severe
dverse events included 2 patients with hemorrhagic
ystitis that subsequently resolved, although 1 patient
ater had BK virus identiﬁed in the urine. One patient
eveloped acute respiratory distress syndrome during
tudy treatment, and 5 patients developed grade 3
hrombocytopenia. Seven patients had severe infec-
ions while receiving study treatment or shortly there-
fter, including cytomegalovirus infection (n  2),
ungal infection (n  2), and bacterial sepsis (n  3).
urvival
The median survival for all patients was 121 days
range, 12-721 days); 5 patients survived and were in
ctive follow-up at a median of 496 days (range, 97-
21 days). Four of the surviving patients had a re-
ponse of their GVHD to denileukin diftitox by study
ay 36, and the other survivor responded to salvage
reatment. One surviving patient who responded to
enileukin diftitox is off all immunosuppression with
o active chronic GVHD. The other surviving pa-
ients continue to receive systemic immunosuppres-
ion for chronic GVHD. Of the 6 responding patients
t study day 100, 2 subsequently died; one of idio-
athic interstitial pneumonitis and the other of re-
apsed multiple myeloma with concomitant chronic
HVD. In the 16 patients categorized as nonre-
able 3. GVHD Response
Variable Day 36 CR
Day 100
CR PR
verall response 9/22 (41%) 4/22 (18%) 2/22 (9%)
esponse by Organ
Skin 9/21 (43%) 4/21 (19%) 1/21 (5%)
Intestine 2/9 (22%) 2/9 (22%) 0
Liver 1/9 (11%) 0 1/9 (11%)
esponse by GVHD
grade
B 5/7 (71%) 2/7 (29%) 1/7 (14%)
C 2/7 (29%) 0 1/7 (14%)
D 2/8 (25%) 2/8 (25%) 0
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Denileukin Diftitox for aGVHD
Bponders at study day 100, 1 patient is alive after
alvage therapy, 1 patient died from relapsed acute
yelogenous leukemia with concomitant aGVHD,
nd 14 patients died from GVHD or infection.
ISCUSSION
This study demonstrates that denileukin diftitox
as activity in treating steroid-resistant aGVHD. Our
verall response rates at study day 36 and 100 of 41%
nd 27%, respectively, are similar to other studies
sing a variety of agents to treat steroid-resistant
GVHD [17-25]. Some patients in our study clearly
ad a response of their aGVHD to study treatment
ut were coded as nonresponders because of a ﬂare of
heir GVHD symptoms before the deﬁned study end
oints of day 36 and 100 or because they died from
nfection or a transplant-related complication. Be-
ause complications from infections are often related
o aGVHD or treatment of aGVHD, we believe that
t was important to code these patients as nonre-
ponders despite the clinical improvement in their
GVHD symptoms. Ho et al. [25] at the Dana Farber
ancer Institute have also described their experience
ith denileukin diftitox in a similar patient popula-
ion. In their study, 32 patients were enrolled, but only
4 were evaluable for response: 8 patients achieved a
R, and 9 patients achieved a PR. In this dose-ﬁnding
tudy, the maximum tolerated dose was 9 g/kg de-
ivered on study days 1, 3, 5, 15, 17, and 19. Of note,
he dose-limiting toxicity in this study was increased
epatic transaminases when the drug was adminis-
ered at 9 g/kg daily on days 1 to 5 and 15 to 19: this
s similar to the dose schedule and toxicity seen in the
patients treated at dose level 2 in our study.
Denileukin diftitox administered at dose level 1
emonstrated acceptable toxicity in this patient pop-
lation. This dose level was derived by using half the
ood and Drug Administration–approved dose of de-
ileukin diftitox to treat cutaneous T-cell lymphoma.
nfusion-related toxicities, as reported in patients with
utaneous T-cell lymphoma [26], were not seen in our
tudy, possibly because of the high dose of steroids
nd lack of malignant T cells in our patient popula-
ion. At this dose level, only 2 patients had mild
ascular leak symptoms with isolated lower extremity
dema and hypoalbuminemia. Although most patients
n this study did have some hypoalbuminemia, the
edian albumin level before and after study treatment
id not vary signiﬁcantly. Other adverse events and
oxicities seen at dose level 1 were events that com-
only occur in allogeneic stem cell transplantation
atients, such as infection, cytopenias, and bleeding.
Agents that may affect T-cell function after allo-
eneic stem cell transplantation raise concerns for
ngraftment, malignancy control, infection, and Ep- h
B&MTtein-Barr virus–related posttransplantation lympho-
roliferative disease. These concerns were not ob-
erved in this study; no patient developed
osttransplantation lymphoproliferative disease or
raft rejection, and the 2 patients whose underlying
isease relapsed had ongoing GVHD. The infections
een in patients on this study are those that can com-
only be observed in patients with GVHD who are
eceiving high-dose steroids.
We deﬁned steroid-resistant aGVHD as disease
hat failed primary therapy with systemic corticoste-
oids (Table 1). Patients were not allowed to have
eceived systemic immunosuppressive therapy as
reatment for aGVHD other than systemic corticoste-
oids and continuation of prior GVHD prophylactic
edication. Our patient population was different in
his manner from the Dana Farber study in that we
elected for a patient population that was earlier in
heir aGVHD course, with fewer complications and
ess immunosuppressive treatment.
We also included patients whose aGVHD ﬂared
fter tapering of corticosteroids to 2 mg/kg meth-
lprednisolone (or equivalent), and this group com-
rised most patients on study. We included this group
f patients on study because their primary therapy of
GVHD failed, and we believe that they still experi-
nced excess morbidity and mortality from GVHD. In
he retrospective review of secondary treatment of
GVHD by Martin et al. [17], 91 evaluable patients
ad a ﬂare of aGVHD during the taper of steroids and
ere treated with secondary rechallenge of corticoste-
oids. Responses were seen in 47% of patients; how-
ver, less than half of these responses showed durable
verall improvement. The dose of steroid at which
are of aGVHD occurred was not described in this
tudy. In our study, most patients in this group had a
are of aGVHD symptoms before they were tapered
o1 mg/kg methylprednisolone. Patients with a ﬂare
f aGVHD with steroid taper represented most pa-
ients on our study, because this is probably a more
ommon clinical scenario than stable refractory or
rogressive aGVHD. It is possible that rechallenge
ith corticosteroids may have affected the response
ate of patients who met criteria III (Table 1); how-
ver, responses were not assessed until study days 36
nd 100, by which time steroid taper had already
esumed. CR of aGVHD at study day 36 was demon-
trated in 4 of 8 patients who met criteria I or II and
n 5 of 14 patients who met criteria III (data not
hown). Survival was poor in all categories of classify-
ng steroid-resistant aGVHD. Only 2 responders who
et criteria III and 1 each who met the other criteria
emained alive, thus demonstrating the poor overall
rognosis of this group of patients in our study.
The grade of aGVHD at study entry was nearly
venly split among grades B, C, and D (Table 2);
owever, most responses were seen in patients with
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1rade B disease (Table 3). The most common mani-
estation of aGVHD in this study was skin disease, and
astrointestinal tract and liver disease were present in
patients each (Table 3). Patients with liver disease
ad the poorest outcomes; only 1 patient had a CR at
tudy day 36, 1 patient had a PR at study day 100, and
o patient survived. Two patients with stage IV gas-
rointestinal aGVHD and overall grade D disease had
CR of their GVHD by study day 36 which was
aintained until study day 100. Denileukin diftitox
ay preferentially target activated lymphocytes in the
kin and, to a lesser extent, the gastrointestinal tract,
ut larger studies are needed to address this question.
Long-term survival continues to be a problem in
atients with steroid-refractory aGVHD, primarily
rom problems relating to GVHD and infection. The
edian survival of the 4 patients in our study who
esponded to denileukin diftitox and are alive is 496
ays, thus suggesting that long-term survival is achiev-
ble in some patients.
The exact mechanism of the effect that denileukin
iftitox has on the IL-2R warrants further investiga-
ion because of the increasing evidence that depletion
f CD4/CD25-positive cells may adversely affect en-
raftment and promote the development of GVHD
27-29]. Also, a recent phase III study of daclizumab,
monoclonal antibody that efﬁciently depletes CD25-
ositive cells, demonstrated negative results as part of
rimary therapy for aGVHD [30]. The Dana Farber
tudy of denileukin diftitox to treat steroid-refractory
GVHD did note that CD3/CD25-positive cells were
ot signiﬁcantly affected after treatment with denileu-
in diftitox [25], and previous studies in cutaneous
-cell lymphoma and non-Hodgkin lymphoma did
ot ﬁnd that CD25 positivity correlated with the dis-
ase response to denileukin diftitox [11,26,31]. It is
ossible that the effect of denileukin diftitox on the
igh-afﬁnity IL-2R does not correlate with just CD25
xpression but may be better expressed by more spe-
iﬁc markers for the intermediate- and high-afﬁnity
L-2R, such as CD122 and CD132. The population of
ctivated lymphocytes affected by denileukin diftitox
ay be smaller and have a more narrow immuno-
odulatory role than the entire population of CD25-
ositive cells. Denileukin diftitox may also be modu-
ating aGVHD by another mechanism altogether.
In conclusion, this study demonstrates that de-
ileukin diftitox has activity in treating steroid-resis-
ant aGVHD. The drug was tolerated well at dose
evel 1; however, dose level 2 seems to have unaccept-
ble toxicity. Overall survival in this population of
atients remains poor because of continued problems
ith infection and GVHD. Further study in the treat-
ent of steroid-resistant aGVHD is needed to im-
rove long-term control of aGVHD and complica-
ions related to infection. One issue surrounding the
ack of sustainable response in our study may be the
92imited treatment plan we used. Studies examining
aintenance treatment with denileukin diftitox or
ombinations with other immunosuppressive agents,
s well as better supportive care and treatment of
nfection, may address these issues. Intervening with
enileukin diftitox as part of primary treatment or
rophylaxis of GVHD may beneﬁt larger numbers of
llogeneic stem cell transplantation patients, and study
s warranted in these areas. Further study of the effects
f denileukin diftitox on lymphocyte subsets and their
ole in the pathophysiology of GVHD, engraftment,
nd graft-versus-leukemia may also help to deﬁne the
ole of this agent in the treatment of allogeneic stem
ell transplantation patients.
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